Betahistine is a histamine analogue and a potent H1 receptor agonist with weak H3 receptor antagonist activity. It is primarily used for the symptomatic management of vertigo and Meniere's disease. The 48mg strength is a high-dose, sustained-release formulation designed for once-daily administration, improving compliance in chronic vestibular disorders. It acts by improving microcirculation in the inner ear and modulating vestibular nuclei activity in the central nervous system.
Adult: For 48mg SR tablet: One tablet (48mg) once daily, preferably with a meal. The usual maintenance dose for Meniere's syndrome is 24mg to 48mg per day. The 48mg SR is the maximum recommended daily dose.
Note: Swallow the SR tablet whole with a glass of water, preferably with or just after food to improve tolerability. Do NOT crush, chew, or break the tablet, as this will destroy the sustained-release properties and may lead to a rapid dose dump, increasing side effects. The tablet can be taken at any time of day, but a consistent schedule is recommended.
Betahistine's primary mechanism in vestibular disorders is dual: 1) Peripheral: It acts as a partial agonist at histamine H1 receptors on the blood vessels of the inner ear (stria vascularis), leading to vasodilation and improved microcirculation. This helps reduce endolymphatic pressure, a key factor in Meniere's disease. 2) Central: It acts as an antagonist at presynaptic histamine H3 autoreceptors and heteroreceptors in the vestibular nuclei of the brainstem. This blockade increases the release of histamine and other neurotransmitters (like serotonin) from neurons, leading to an inhibitory effect on the vestibular nuclei, thereby reducing the sensation of vertigo and improving balance.
Pregnancy: Category B: Animal studies have not shown teratogenic risk, but adequate and well-controlled studies in pregnant women are lacking. Use only if clearly needed and potential benefit justifies potential risk to the fetus.
Driving: Caution advised. Although betahistine is less sedating than other anti-vertigo drugs, it can cause drowsiness, dizziness, or blurred vision in some individuals, especially at treatment initiation. Patients should not drive or operate machinery until they know how the medication affects them.
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Selegiline, Phenelzine | MAOIs inhibit the primary metabolic pathway of betahistine. Concurrent use can lead to a significant increase in betahistine plasma levels, potentiating its effects and side effects (especially histaminergic effects like headache, flushing, hypotension). | Major - Contraindicated or requires extreme caution and dose reduction. |
| Antihistamines (H1 antagonists) e.g., Cetirizine, Loratadine, Diphenhydramine | Theoretical antagonism of betahistine's therapeutic effect at H1 receptors. May reduce efficacy in treating vertigo. | Moderate - Monitor for reduced therapeutic response. |
| Antihypertensive Drugs | Betahistine may cause vasodilation and potentially additive hypotensive effects. | Moderate - Monitor blood pressure, especially during initiation. |
| Other drugs metabolized by MAO (e.g., certain sympathomimetics) | Potential for unpredictable interactions. | Moderate - Use with caution. |
Same composition (Betahistine (48mg)), different brands: